Correction: Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway

Ping Gao¹Xiaoyi Du²Lili Liu¹Hua Xu¹Maochang Liu¹Xin-Lei Guan³Chengliang Zhang^4*

• ¹Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
• ²Huazhong University of Science and Technology Tongji Medical College Union Hospital, Wuhan, China
• ³Wuhan Fourth Hospital, Wuhan, China
• ⁴Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, China

There were mistakes in figure 3D and figure 6E as published. In figure 3D, the image of Tac group (the second group) was misused. In figure 6E, the western blot of p62 was misused. The corrected figure 3D and figure 6E appear below. Last Name author1 et al. Frontiers Media SA 2 FIGURE 3. The cell protective and ROS scavenge effect of Astragaloside IV in HK-2 cells. (D) The levels of intracellular ROS were detected with 2', 7'-dichlorodihydrofluorescein diacetate (H2DCFDA) assay. FIGURE 6. Astragaloside IV increased Keap1 degradation and p62 phosphorylation in vivo. (E) The p62 as well as phosphorylated p62 protein levels.